Originally published by our sister publication, Pain Medicine News.
The FDA has approved a supplemental New Drug Application (sNDA) for tofacitinib (Xeljanz/Xeljanz XR, Pfizer) for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.